Biotechnology · Transcription factor drugs
Altay Therapeutics
A six person company in San Carlos drugging proteins the industry wrote off. Its lead compound, an oral DUX4 inhibitor for muscular dystrophy, has an FDA orphan designation and no registered clinical trial.
A screen of 2.8 million compounds
In September 2021 a two year old California company sent a progress report to Friends of FSH Research, a patient funded foundation that had given it seed money to chase one protein. The report runs three paragraphs and reads like a lab notebook.
Genetics came first. “Using Altay’s platform technology, we performed genetic studies and identified key residues for DUX4 activity.” Then molecular simulations, to find a pocket nobody had mapped. Then an in silico screen of 2.8 million compounds, which produced a hit the company named DX5. Twenty one analogs later there was a second generation molecule, DX5001, described in the same report as 20 to 30 times more potent.
The target was DUX4, a transcription factor that healthy adult muscle keeps switched off. In facioscapulohumeral muscular dystrophy it switches back on and muscle cells die. Five years on, that chemistry has a name, DX5057, an orphan designation, a CEO who says the clinic is close, and nothing on the trial register.
Why nobody drugs a transcription factor
One transcription factor can switch hundreds of genes on or off, which makes them obvious targets and terrible ones. They lack the deep, fixed pockets small molecules like to sit in, and large stretches of them are intrinsically disordered, so there is no single shape to design against.
Altay’s claim, repeated across four NIH grant applications and its own website, is that the pockets exist but appear only while the protein moves, and that genetic screening plus simulation can find them. It calls the approach therapeutic area agnostic, which is another way of saying the platform picks the target and the disease follows.
The FSHD field tested that in 2026. Fulcrum Therapeutics put losmapimod, a p38 inhibitor that lowers DUX4 indirectly, through a 260 patient phase 3; results published in September 2026 showed no significant difference from placebo on any endpoint at 48 weeks. In June 2026 Epicrispr Biotechnologies reported gains in lean muscle volume in the first three evaluable patients dosed with an intravenous therapy that silences DUX4. Neither result is Altay’s, but both sharpen its structural argument: a pill instead of an infusion.
A father, a son, and a fibrosis drug
Ali Ozes took a PhD at Indiana University Bloomington in 2016, describing an oligonucleotide inhibitor of the long non coding RNA HOTAIR, then did two years at Johnson and Johnson before joining a startup out of Kevan Shokat’s UCSF lab.
“Using this approach, we successfully drugged two previously undruggable transcription factors involved in fibrosis and Ewing’s Sarcoma which are now advancing in our pipeline,” he wrote in a foundation investigator profile.
He founded Altay in 2019 with his father, Osman Nidai Ozes, who led the pirfenidone program at InterMune, bought by Roche in 2014. Pirfenidone, sold as Esbriet, was the first drug approved for idiopathic pulmonary fibrosis. That lineage is the whole pitch of the original Y Combinator entry, still live and still describing a liver company.
From liver disease to muscle
The Winter 2020 profile promises small molecules for chronic liver disease and sets a schedule: “With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.” None of that happened on that timetable, and the liver is gone from the pipeline chart.
What accumulated instead was other people’s money and lab space. Bristol Myers Squibb gave Altay a Golden Ticket in November 2021, a free year of bench at MBC BioLabs. In September 2022 SOLVE FSHD, the venture philanthropy funded with $100 million by lululemon founder Chip Wilson, who has FSHD himself, put US$3 million in. “SOLVE FSHD’s targeted investment into Altay Therapeutics will support the company’s growth and will help identify a DUX4 inhibitor for clinical trials,” said Eva Chin, its executive director, who joined the board alongside chairman Eric Bjerkholt.
Between 2022 and 2024 came five SBIR Phase I awards worth $1,573,527: four NIH grants covering STAT3 in pulmonary fibrosis, ovarian cancer and scleroderma lung disease plus DUX4 in FSHD, and one NSF grant for the EWS-FLI1 fusion behind Ewing’s sarcoma. Astellas added a Future Innovator Prize in December 2023, another sponsored year of bench.
New management, old promise
The company that filed those grants was run by its scientific founder. The one on the website in September 2026 is not: Jim Breitmeyer is chief executive, Mike Grey executive chair, Alejandro Dorenbaum chief medical officer, Ali Ozes founder and chief scientific officer.
In July 2026 Altay joined the FSHD Industry Collaborative, run by the FSHD Society, SOLVE FSHD and the FSHD Clinical Trial Research Network. Breitmeyer used the announcement to set a date, saying Altay was joining “as we collaborate with the FSHD Society and SOLVE FSHD to develop our novel oral DUX4 inhibitor DX5057 to initiate clinical trials later this year.” Two months later, a search of ClinicalTrials.gov for the company and for the compound returns nothing.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Federal grants | Five SBIR Phase I awards totaling $1,573,527: four NIH grants and one NSF grant. SBIR.gov records zero Phase II awards and zero Phase II dollars. | Public record |
| Orphan designation | Reported for DX5057 by two FSHD patient organizations, dated Nov 26 and Dec 3, 2025. The FDA designation search tool returned a service error on Sep 22, 2026, so the agency record was not read directly. | Independent |
| Registered trial | None. ClinicalTrials.gov searches for Altay as sponsor and for DX5057 returned no studies on Sep 22, 2026. | Not found |
| Peer reviewed data | None found. A PubMed affiliation search returns four Altay papers, none about DX5057, DUX4 or STAT3 inhibition. | Not found |
| Preclinical efficacy | The company says DX5057 matches leading intravenous gene targeting therapies, with oral dosing. No dataset or publication behind that comparison has been released. | Company-stated |
| Clinic timing | The YC profile promises phase I by mid 2022; the pipeline chart shows Phase 1/2a in 2025 and 2026; the CEO said in July 2026 that trials would start that year. Nothing is registered. | Differs from the record |
| Which asset leads | Creative Destruction Lab lists PCE1911 for Ewing’s sarcoma as the lead and E46 for lung fibrosis second. The current site leads with DX5057. | Descriptions differ |
| Investment | SOLVE FSHD announced US$3 million on Sep 21, 2022. No amount is disclosed for Y Combinator, Tachyon VC or the two incubator prizes. | Partner-stated |
| Equity filings | No Form D for Altay Therapeutics in SEC EDGAR as of Sep 22, 2026. | Not found |
Read plainly: the grant record is real and detailed, and every dollar of it is Phase I. Seven years in, Altay has a designated orphan drug, a clinical team and no human data of any kind. The claim that matters most, that an oral pill matches intravenous gene targeting therapies, rests on the company saying so.
What to watch
- An IND and a ClinicalTrials.gov registration for DX5057. The chief executive said trials would begin in 2026.
- A first SBIR Phase II award. Five Phase I grants with no conversion is a pattern.
- Any publication or dataset behind the comparison with intravenous DUX4 therapies.
- A priced equity round. Nothing public shows venture capital on the cap table.
- The STAT3 program, which carries three of the five federal grants and has no named compound.
In their words
“Using Altay’s platform technology, we performed genetic studies and identified key residues for DUX4 activity.”
Ali Ozes, progress report to Friends of FSH Research, September 2021 · Foundation
“Using this approach, we successfully drugged two previously undruggable transcription factors involved in fibrosis and Ewing’s Sarcoma which are now advancing in our pipeline.”
Ali Ozes, investigator profile, Friends of FSH Research, 2021 · Foundation
“We are honoured to work with SOLVE FSHD and Dr. Chin to fast-track our research and to collaborate to find a cure for FSHD.”
Ali Ozes, then co-founder and CEO, SOLVE FSHD announcement, September 2022 · Partner release
“SOLVE FSHD’s targeted investment into Altay Therapeutics will support the company’s growth and will help identify a DUX4 inhibitor for clinical trials.”
Eva Chin, executive director, SOLVE FSHD, September 2022 · Partner release
“as we collaborate with the FSHD Society and SOLVE FSHD to develop our novel oral DUX4 inhibitor DX5057 to initiate clinical trials later this year.”
James Breitmeyer, CEO, FSHD Industry Collaborative, July 2026 · Consortium release
“With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.”
Altay Therapeutics, Y Combinator profile, live September 2026 · Company-stated
“DX5057 will need to move into larger clinical trials before it ever reaches the market and one of the biggest hurdles will be enrolling enough participants.”
An Sasala, FSHD Society, January 2026 · Patient organization
Related companies
Sources
- Public recordSBIR.gov portfolio, five Phase I awards
- Public recordNIH awards R43AR081195, R43HL162149, R43CA272146, R43HL172594
- Public recordClinicalTrials.gov searches, no studies
- Public recordPubMed affiliation and author searches
- Public recordSEC EDGAR searches, no Form D
- Public recordLosmapimod in FSHD, the REACH study
- IndependentTargeting disease-causing transcription factors
- FoundationProgress update on a DUX4 inhibitor
- FoundationAli Ozes investigator profile
- FoundationOrphan drug designation for DX5057
- Patient organizationArt’s call to action
- IndependentFSHD Industry Collaborative expands
- IndependentInterim EPI-321 data in FSHD
- IndependentGolden Tickets to promising biotechs
- Independent2023 Future Innovator Prize
- PartnerSOLVE FSHD invests US$3 million in Altay
- CompanyAltay Therapeutics website, pipeline and team
- CompanyY Combinator company profile
- CompanyCompany page listing PCE1911 and E46
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
